Clinical trials
Renal Carcinoma clinical trials
Below are recruiting renal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 287 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07293351RecruitingPhase 1/Phase 2
Testing pumitamig with other drugs for advanced kidney cancer
This study tests a new drug (pumitamig) alone or with ipilimumab or cabozantinib for advanced kidney cancer that cannot be removed by surgery. It aims to find effective treatment options for people whose cancer has spread or is locally advanced.
Palo Alto, CaliforniaAges 18 years+ - NCT06726421RecruitingPhase 3
Systemic therapy with or without radiation for kidney cancer that has spread to a few spots
This trial compares standard systemic therapy (medication) alone versus systemic therapy plus targeted radiation to the cancer spots for people with kidney cancer that has spread to a limited number of places (up to 5 spots). It aims to see if adding radiation helps control the cancer better.
Fuzhou, FujianAges 18 years+ - NCT07551349RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Kidney Cancer
This trial tests a new type of cell therapy (CAR-NK cells) designed to target kidney cancer that has spread or cannot be removed with surgery. The cells are engineered in the lab to recognize and attack cancer cells, and may help patients whose cancer has grown despite previous treatments.
Shenzhen, GuangdongAges 18 years+ - NCT04510129Recruiting
Cancer biospecimen collection study for immunotherapy patients
This study collects samples (like tissue biopsies and imaging information) from people with certain cancers who are starting anti–PD-1/PD-L1 immunotherapy. It helps researchers gather material to study how these treatments work.
San Francisco, CaliforniaAges 18 years+ - NCT04895709RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
Clovis, CaliforniaAges 18 years+ - NCT07187869RecruitingPhase 1
Cabozantinib plus nivolumab for kidney cancer with bone spread
This study tests whether adding a drug called cabozantinib to standard nivolumab treatment helps fight kidney cancer that has spread to bone. It aims to understand how the bone environment changes during treatment.
Houston, TexasAges 18 years+ - NCT05155033RecruitingPhase 2
A trial of PD-1 plus aldesleukin for melanoma or kidney cancer
This Phase 2 study tests whether combining anti–PD-1 treatment with aldesleukin can shrink or control metastatic melanoma or metastatic kidney (renal cell) cancer. It is mainly for people who have either not had anti–PD-1 before, or whose cancer did not respond to prior anti–PD-1 treatment.
Bethesda, MarylandAges 18–120 - NCT05536141RecruitingPhase 1
Study of AB521 for kidney cancer and other solid tumors
This early-stage trial tests AB521, alone and in combination with other medicines, in people with advanced solid tumors—especially clear cell kidney cancer. It aims to find a safe dose and see whether the treatment could help shrink tumors or control the disease.
Birmingham, AlabamaAges 18 years+ - NCT06983210RecruitingPhase 2
Combination treatment for advanced bladder cancer
This trial tests a new drug combination for people with advanced bladder or urinary tract cancer that has not been treated before. The goal is to see if adding AM80 to standard chemotherapy and immunotherapy works better.
Nagoya, Aichi-kenAges 18–79 - NCT00001238Recruiting
Understanding kidney cancer genes in families
This research study helps doctors understand inherited kidney cancers and related conditions that run in families. Researchers collect medical information and blood samples to identify genetic causes and improve how these conditions are diagnosed and treated.
Bethesda, MarylandAges 2 years+ - NCT04693377Recruiting
Freezing tumor treatment plus targeted radiation for painful bone spread
This study tests whether combining a “freezing” procedure (cryoablation) with focused external radiation (SBRT) can reduce pain from bone metastases. It’s for people with certain cancers that have spread to bone and are having significant pain in a specific bone spot.
Houston, TexasAges 18 years+ - NCT03977571Recruiting
Surgery plus cancer drugs for kidney cancer that spread
This trial studies whether removing the kidney tumor with “deferred cytoreductive nephrectomy” (surgery at a later time) works best for people whose metastatic kidney cancer is already present. It compares a standard treatment approach using either immunotherapy (nivolumab/ipilimumab) or a targeted pill plus immunotherapy (TKI/IO), with planned surgery afterward.
Aarhus, Central Region of DenmarkAges 18 years+ - NCT07023432RecruitingPhase 2
Belzutifan vs. watchful waiting for slow-growing kidney cancer
This trial compares two approaches for people with slow-growing, metastatic clear cell kidney cancer: taking a daily pill (belzutifan) or monitoring the cancer closely without treatment. The goal is to see if starting treatment early can help control the cancer longer than waiting.
Houston, TexasAges 18 years+ - NCT06040762Recruiting
Get moving before bladder cancer surgery
This study tests whether a home-based exercise program before surgery can help improve physical function in people with bladder or upper tract urothelial cancer. If you are planning to have surgery to remove your bladder or upper urinary tract, you may be able to join.
Seattle, WashingtonAges 18 years+ - NCT06638931RecruitingPhase 2
Nivolumab for rare solid tumors with high PD-L1
This trial is testing a drug called Nivolumab (an immunotherapy) for people with rare solid tumors that have high levels of PD-L1. It might be an option if you have tried other treatments and they stopped working or caused too many side effects.
Fortaleza, CearáAges 18 years+ - NCT07046832Enrolling by invitation
Augmented reality needle guidance for soft tissue biopsy
This trial tests a new augmented reality system that helps guide the needle during a soft-tissue biopsy. It may make the procedure more accurate and easier for your doctor.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04113486Recruiting
NMAP protein in new kidney or liver tumors
This study looks at a protein called NMAP in people who have a new kidney or liver mass that will be surgically removed. It helps researchers understand how this protein relates to cancer and might lead to better tests or treatments in the future.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06519760Recruiting
68Ga-C1 PET/CT imaging for clear cell kidney cancer
This trial uses a special imaging scan (68Ga-C1 PET/CT) to see kidney cancer more clearly. It helps doctors find and understand clear cell renal cell carcinoma, a common type of kidney cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05917106Recruiting
Testifying methylomics blood test for new kidney cancer monitoring
This study follows people with newly diagnosed kidney cancer who have not started treatment. It tests whether a special blood test can monitor the cancer over time, alongside standard follow-up after planned surgery.
Nanjing, JiangsuAges Any age - NCT06794229RecruitingPhase 2
Zanzalintinib plus nivolumab before surgery for advanced kidney cancer
This trial tests two drugs—zanzalintinib and nivolumab—given before surgery to shrink advanced or hard-to-remove kidney tumors. The goal is to make the tumor easier to remove and improve outcomes.
St Louis, MissouriAges 18 years+ - NCT05768464RecruitingPhase 2
Surgery aftercare for non-clear kidney cancer at high risk
This Phase 2 trial studies an after-surgery treatment for people with non-clear types of kidney cancer who are at high risk of coming back. It aims to lower the chance of recurrence by giving extra therapy after your tumor is completely removed.
Nanjing, JiangsuAges 18–75 - NCT07594106RecruitingPhase 1/Phase 2
New immunotherapy for advanced prostate or kidney cancer
This trial tests new experimental drugs (REGN15505 and REGN4336) designed to target and attack cancer cells in advanced prostate cancer or kidney cancer. These drugs work by boosting your immune system to recognize and destroy cancer, and may be combined with other approved immunotherapy drugs.
Goodyear, ArizonaAges 18 years+ - NCT06910657RecruitingPhase 1
IDOV-Immune vaccine for advanced solid tumors
This trial tests an experimental virus-based treatment for people with advanced solid tumors that have stopped responding to standard therapies. The treatment is designed to infect and destroy cancer cells while boosting the immune system.
St Louis, MissouriAges 18 years+ - NCT04987086Recruiting
68Ga PSMA PET-CT for kidney cancer spread
This study checks whether a special PET-CT scan using 68Ga PSMA can better find where renal cell carcinoma has spread. It may help doctors plan the right next steps by confirming suspected metastases on CT.
Lanzhou, GansuAges 18–90
Hear when a new Renal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for renal carcinoma?
- Yes. Clin2 currently lists 287 recruiting renal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a renal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a renal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.